Follow
John Wagstaff
John Wagstaff
College of Medicine, Swansea University, UK
Verified email at swansea.ac.uk
Title
Cited by
Cited by
Year
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
79952015
Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...
New England Journal of Medicine 373 (19), 1803-1813, 2015
60342015
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
36042017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
31202019
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ...
Journal of clinical oncology 28 (6), 1061-1068, 2010
30312010
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
20992016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
17672017
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ...
The Lancet Oncology 19 (11), 1480-1492, 2018
13762018
Therapeutic vaccines for cancer: an overview of clinical trials
I Melero, G Gaudernack, W Gerritsen, C Huber, G Parmiani, S Scholl, ...
Nature reviews Clinical oncology 11 (9), 509-524, 2014
8392014
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 40 (2), 127, 2022
6642022
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update
CN Sternberg, RE Hawkins, J Wagstaff, P Salman, J Mardiak, CH Barrios, ...
European journal of cancer 49 (6), 1287-1296, 2013
5092013
Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical …
A Bex, P Mulders, M Jewett, J Wagstaff, JV Van Thienen, CU Blank, ...
JAMA oncology 5 (2), 164-170, 2019
4542019
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis
AEM Dirkx, MGA oude Egbrink, J Wagstaff, AW Griffioen
Journal of leukocyte biology 80 (6), 1183-1196, 2006
4152006
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
A Birtle, M Johnson, J Chester, R Jones, D Dolling, RT Bryan, C Harris, ...
The Lancet 395 (10232), 1268-1277, 2020
3802020
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
3712019
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies
GC Jayson, J Zweit, A Jackson, C Mulatero, P Julyan, M Ranson, ...
Journal of the National Cancer Institute 94 (19), 1484-1493, 2002
3292002
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer
S Rodenhuis, M Bontenbal, LVAM Beex, J Wagstaff, DJ Richel, MA Nooij, ...
New England Journal of Medicine 349 (1), 7-16, 2003
3282003
Tumor Angiogenesis Modulates Leukocyte-Vessel Wall Interactions in Vivo by Reducing Endothelial Adhesion Molecule Expression
AEM Dirkx, MGA oude Egbrink, MJE Kuijpers, ST van der Niet, ...
Cancer research 63 (9), 2322-2329, 2003
3172003
Anti‐angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte‐endothelium interactions and infiltration in tumors
AEM Dirkx, MGA Egbrink, K Castermans, DWJ Van Der Schaft, ...
The FASEB Journal 20 (6), 621-630, 2006
2752006
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ...
Annals of Oncology 29 (5), 1235-1248, 2018
2732018
The system can't perform the operation now. Try again later.
Articles 1–20